Literature DB >> 25190157

[Analysis of clinical features and arylsulfatase B gene mutation in thirteen Chinese children with mucopolysaccharidosis type VI].

Jipeng Zheng1, Yonglan Huang2, Xiaoyuan Zhao1, Huiying Sheng1, Jing Cheng1, Zhihong Zhou1, Xiuzhen Li1, Xiaojian Mao1, Li Liu1.   

Abstract

OBJECTIVE: Mucopolysaccharidosis type VI (MPS VI) or Maroteaux-Lamy syndrome is an autosomal recessive lysosomal storage disease caused by a deficiency of arylsulfatase B(ARSB), which is required in the degradation of dermatan sulfate and chondroitin sulfate. The deficiency of ARSB leads to an accumulation of dermatan sulfate and chondroitin sulfate in lysosomes and gross excretion in the urine.Few articles about clinical study and ARSB gene mutation analysis of Chinese MPS VI patients were published. This study aimed to explore the clinical features and characteristics of ARSB gene in Chinese children with MPS VI.
METHOD: Thirteen children were diagnosed as MPS VI by ARSB enzyme activity determination during the period from 2009 to 2013. Their clinical features, radiological findings and urine glycosaminoglycan (GAG) levels were retrospectively reviewed. Direct sequencing was used to identify any mutation in the ARSB gene. RESULT: Thirteen children were diagnosed at the average age of (3.9 ± 2.2) years with 6 male and 7 female. All of these children presented with severe form and onset at an early age of (1.5 ± 0.8) years.Other clinical features included coarse facies, short stature, skeleton deformity, corneal clouding, hepatosplenomegaly with normal intelligence. The radiological findings in all children were characteristic of dysostosis multiplex, like abnormal development of vertebral bodies of the spine, campylorrhachia and paddle-shaped widened ribs. The MRI in case 2 showed cervical cord compression and multiple cysts degeneration in the corona radiate, cella lateralis and callosum.High urine GAG levels were detected, (307.10 ± 112.14) mg/L (Normally below 70 mg/L) and (722.28 ± 245.68) µg/mg creatinine. The ARSB enzyme activity in leukocytes was low, (13.29 ± 6.22) nmol/(mg×h) [Normal range (47-169) nmol/(mg×h)] by fluorogenic assay and (0.24 ± 0.18) U/g [Normal range (1.01-11.47) U/g] by colorimetric assay. A total of 11 mutations were identified by molecular analysis, including seven previously reported mutations (p.L72R, p.G167R, p.G303E, p.F399L, p. T442M, p.Y255X and p.R327X) and four novel mutations (p.Y175D, p.S403X, p.S464X and large deletion including ex. 2, 3). The c.1197C>G (p.F399L) mutation was the most common mutation in this study (31%).
CONCLUSION: The severe form of MPS VI is characterized by early onset and rapid illness progression. Both the radiological findings and increased urine GAG are important clues to diagnose MPS VI.Large decrease or absence of ARSB activity is diagnostic for MPS VI.Four novel mutations of ARSB gene were identified. The reported mutation c.1197C>G (p.F399L) was the hot-spot mutation in this study.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25190157

Source DB:  PubMed          Journal:  Zhonghua Er Ke Za Zhi        ISSN: 0578-1310


  3 in total

Review 1.  Mucopolysaccharidosis type VI (MPS VI) and molecular analysis: Review and classification of published variants in the ARSB gene.

Authors:  Rosella Tomanin; Litsa Karageorgos; Alessandra Zanetti; Moeenaldeen Al-Sayed; Mitch Bailey; Nicole Miller; Hitoshi Sakuraba; John J Hopwood
Journal:  Hum Mutat       Date:  2018-09-17       Impact factor: 4.878

2.  Mutations in ARSB in MPS VI patients in India.

Authors:  Juby Mathew; Sujatha M Jagadeesh; Meenakshi Bhat; S Udhaya Kumar; Saravanamuthu Thiyagarajan; Sudha Srinivasan
Journal:  Mol Genet Metab Rep       Date:  2015-07-17

3.  Epidemiology and Genetics of Mucopolysaccharidosis Type VI in Russia.

Authors:  Elena Voskoboeva; Alla Semyachkina; Ochir Miklyaev; Amina Gamzatova; Svetlana Mikhaylova; Nato Vashakmadze; Galina Baydakova; Olga Omzar; Natalia Pichkur; Ekaterina Zakharova; Sergey Kutsev
Journal:  Front Mol Biosci       Date:  2022-01-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.